Jonathan Gerber
Hematology · New York, NYNPI 1275679201
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,125 of the $3,650 with a category attached, or 85.6%. Novartis accounts for 85.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $3,125 and has fallen 92.2% since, to $244 in 2025.
Across 8 payments — averaging $456.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Regeneron$238
- Pfizer$145
- E.r. Squibb & Sons, L.L.C.$141
Across 45 payments — averaging $25,278 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$558K
- Janssen Research & Development, LLC$376K
- E.r. Squibb & Sons, L.L.C.$101K
- Astrazeneca UK Limited$75K
- AbbVie$28K
What the payments were for
- Consulting fees$3,12586%
- Travel & lodging$2066%
- Food & beverage$2778%
- Education$421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $3,125 |
| Regeneron | 2 | $238 |
| Pfizer | 4 | $145 |
| E.r. Squibb & Sons, L.L.C. | 1 | $141 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$141
How this compares
$3,650 in reported general payments places this provider in the 60th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CresembaIsavuconazonium Sulfate | 19 | $104,147 |
Paid to pharmacies, not to this prescriber.
Other hematology in New York
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.